Type 2 diabetes in Asia: where do we go from here?

Soares, Mário J.; Müller, Manfred J.

doi:10.1038/ejcn.2017.94

Cited by 5 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While we decide what is of importance to our discipline, we should engage in focussed discussion in setting a nutrition agenda for the future. With this in mind, we have initiated a series of special issues; one on type 2 diabetes in Asia [12], another on recent advances in energy metabolism [13], with others in the pipeline. A decade ago, a group of scientists pondered the challenges that we would face in the next 30 years [14].…”

Section: Nutrition Agendamentioning

confidence: 99%

Thirty years of EJCN: a time for reflection

Soares

Müller

2018

Eur J Clin Nutr

View full text Add to dashboard Cite

Section: Nutrition Agendamentioning

confidence: 99%

Thirty years of EJCN: a time for reflection

Soares

Müller

2018

Eur J Clin Nutr

View full text Add to dashboard Cite

“…More than 90% of diabetes cases were dominated by T2DM [1]. Worldwide cases of T2DM are predicted to reach 592 million in 2035, and Asia is the main area affected by this disease, especially in China and India [2,3]. This is likely caused by rapid changes in lifestyle behaviors in Asia.…”

Section: Introductionmentioning

confidence: 99%

“…This is likely caused by rapid changes in lifestyle behaviors in Asia. There is increasing carbohydrate and saturated fat intake and decreasing intake of quality protein, healthy fruits, and vegetables, which may lead to dysregulation of lipid, protein, and carbohydrate metabolism and an increased risk of T2DM [1,3].…”

Section: Introductionmentioning

confidence: 99%

Computational Study of Asian Propolis Compounds as Potential Anti-Type 2 Diabetes Mellitus Agents by Using Inverse Virtual Screening with the DIA-DB Web Server, Tanimoto Similarity Analysis, and Molecular Dynamic Simulation

Syaifie

Harisna²,

Nasution

et al. 2022

Molecules

View full text Add to dashboard Cite

Propolis contains a wide range of pharmacological activities because of their various bioactive compounds. The beneficial effect of propolis is interesting for treating type-2 diabetes mellitus (T2DM) owing to dysregulation of multiple metabolic processes. In this study, 275 of 658 Asian propolis compounds were evaluated as potential anti-T2DM agents using the DIA-DB web server towards 18 known anti-diabetes protein targets. More than 20% of all compounds could bind to more than five diabetes targets with high binding affinity (<−9.0 kcal/mol). Filtering with physicochemical and pharmacokinetic properties, including ADMET parameters, 12 compounds were identified as potential anti-T2DM with favorable ADMET properties. Six of those compounds, (2R)-7,4′-dihydroxy-5-methoxy-8-methylflavone; (RR)-(+)-3′-senecioylkhellactone; 2′,4′,6′-trihydroxy chalcone; alpinetin; pinobanksin-3-O-butyrate; and pinocembrin-5-methyl ether were first reported as anti-T2DM agents. We identified the significant T2DM targets of Asian propolis, namely retinol-binding protein-4 (RBP4) and aldose reductase (AKR1B1) that have important roles in insulin sensitivity and diabetes complication, respectively. Molecular dynamic simulations showed stable interaction of selected propolis compounds in the active site of RBP4 and AKR1B1. These findings suggest that Asian propolis compound may be effective for treatment of T2DM by targeting RBP4 and AKR1B1.

show abstract

“…1,2 This knowledge however is not sufficient to make an impact on public health, through obesity prevention at the population level. As with type 2 diabetes, 13 the present evidence strongly suggests that 'society as a whole must act to address the obesity epidemic', 14,15 and those of us who care enough, have to 'rise up...against the organization of the misery' (Pablo Neruda, cited in ref 16). …”

mentioning

confidence: 99%